Trial · NCT03437447
Results by group75
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 75
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of L-Praziquantel (L-PZQ) | Cisticid | 441.53 | Standard Deviation 345.70 | Hour*nanogram per milliliter (h*ng/ml) | |
| Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of L-Praziquantel (L-PZQ) | Biltricide First Administration | 547.41 | Standard Deviation 384.82 | Hour*nanogram per milliliter (h*ng/ml) | |
| Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of L-Praziquantel (L-PZQ) | Biltricide Second Administration | 460.25 | Standard Deviation 343.37 | Hour*nanogram per milliliter (h*ng/ml) | |
| Maximum Observed Plasma Concentration (Cmax) of L-Praziquantel (L-PZQ) | Cisticid | 310.87 | Standard Deviation 249.02 | ng/mL | |
| Maximum Observed Plasma Concentration (Cmax) of L-Praziquantel (L-PZQ) | Biltricide First Administration | 426.42 | Standard Deviation 324.01 | ng/mL | |
| Maximum Observed Plasma Concentration (Cmax) of L-Praziquantel (L-PZQ) | Biltricide Second Administration | 363.20 | Standard Deviation 333.50 | ng/mL | |
| Time to Reach Maximum Plasma Concentration (Tmax) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ) | Cisticid | L-PZQ | 2.5 | Full Range 1.5 to 5.5 | hours |
| Time to Reach Maximum Plasma Concentration (Tmax) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ) | Biltricide First Administration | L-PZQ | 2 | Full Range 1 to 3.5 | hours |
| Time to Reach Maximum Plasma Concentration (Tmax) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ) | Biltricide Second Administration | L-PZQ | 2.5 | Full Range 1 to 4.5 | hours |
| Time to Reach Maximum Plasma Concentration (Tmax) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ) | Cisticid | Rac-PZQ | 2.5 | Full Range 1.5 to 5.5 | hours |
| Time to Reach Maximum Plasma Concentration (Tmax) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ) | Biltricide First Administration | Rac-PZQ | 2 | Full Range 1 to 3.5 | hours |
| Time to Reach Maximum Plasma Concentration (Tmax) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ) | Biltricide Second Administration | Rac-PZQ | 2.5 | Full Range 1 to 4.5 | hours |
| Time Prior to the First Measurable (Non-zero) Concentration (Tlag) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ) | Cisticid | L-PZQ | 1 | Full Range 0.25 to 3 | hours |
| Time Prior to the First Measurable (Non-zero) Concentration (Tlag) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ) | Biltricide First Administration | L-PZQ | 1 | Full Range 0.25 to 2.5 | hours |
| Time Prior to the First Measurable (Non-zero) Concentration (Tlag) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ) | Biltricide Second Administration | L-PZQ | 1 | Full Range 0.25 to 3.5 | hours |
| Time Prior to the First Measurable (Non-zero) Concentration (Tlag) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ) | Cisticid | Rac-PZQ | 0.75 | Full Range 0.00 to 2.00 | hours |
| Time Prior to the First Measurable (Non-zero) Concentration (Tlag) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ) | Biltricide First Administration | Rac-PZQ | 0.75 | Full Range 0.25 to 2.00 | hours |
| Time Prior to the First Measurable (Non-zero) Concentration (Tlag) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ) | Biltricide Second Administration | Rac-PZQ | 0.75 | Full Range 0 to 2.5 | hours |
| Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ) | Cisticid | L-PZQ | 468.52 | Standard Deviation 352.29 | h*ng/ml |
| Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ) | Biltricide First Administration | L-PZQ | 584.23 | Standard Deviation 410.05 | h*ng/ml |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03437447/results